GlycoBac, a biotech company created at the University of Wyoming and based in Laramie, has recently partnered with MilliporeSigma in hopes of developing a rhabdovirus-free platform for gene therapy development and viral vaccines. This partnership aims to allow GlycoBac to expand its marketing and become a larger player in the biotech market.
“It demonstrates a huge, multinational conglomerate has confidence that GlycoBac, a small, biotech startup in Laramie, has been able to create a significant new product that can extend MilliporeSigma’s efforts to serve the broader biotech industry’s needs, worldwide,” said Don Jarvis, a UW professor and president of GlycoBac LLC in a release.
GlycoBac was developed in 2011 when Jarvis’ student, Christoph Geisler, won the John P. Ellbogen $30k Entrepreneurship Competition here at UW. Since then, Jarvis has been able to develop GlycoBac so well that it has drawn attention from a multinational cooperation, MilliporeSigma.
“In addition to significantly extending GlycoBac’s credibility in the biotech sector, GlycoBac will gain the huge benefit of MilliporeSigma’s worldwide marketing, licensing, and distribution prowess,” Jarvis said. This partnership will only be able to further this company in almost every way imaginable.
Through this partnership, GlycoBac will be able to find strength in an already developed company, at a global scale. MilliporeSigma, a merger of two well established companies,
“They recognized a need to extend their product line and market presence in insect cell biomanufacturing platforms,” said Jarvis in regards to MilliporeSigma’s interest. It was this need that drew the company to Laramie, Wyoming.
In the years since 2011 GlycoBac has been able to create a global name for itself while also focusing the spotlight on the university and Wyoming as a place where diversification of the economy is happening.
“I believe GlycoBac is the first UW spinout that can be accurately classified as a “biotech” company,” said Jarvis.
While this partnership is important for the growth of GlycoBac, this company has been able to hold its own in the world since 2011. Through this partnership, GlycoBac will be able to further develop and create an even better name for itself on the global scale.
